DPP4 as a Potential Candidate in Cardiovascular Disease

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is a leading global health concern, with diabetes as a significant risk factor.
• DPP4 inhibitors are a class of anti-diabetic medications.
• Recent cardiovascular outcome trials have established the cardiovascular safety of DPP4 inhibitors.

Purpose of the Study:

• To review recent advances in the understanding of DPP4 inhibitors' role in cardiovascular disease.
• To discuss the potential of DPP4 inhibitors as a therapeutic option for cardiovascular conditions.

Main Methods:

• Literature review of recent studies and clinical trials.
• Analysis of the mechanisms by which DPP4 inhibitors affect cardiovascular risk factors and disease progression.

Main Results:

• DPP4 inhibitors are cardiovascularly safe and demonstrate potential benefits in hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure.
• Beyond glycemic control, DPP4 inhibitors modulate cardiovascular risk factors.
• DPP4 inhibitors exert direct effects on the development and progression of cardiovascular diseases through various pathways.

Conclusions:

• DPP4 inhibitors offer a dual benefit in managing diabetes and cardiovascular health.
• Their multifaceted mechanisms suggest a promising role in cardiovascular therapy.
• Further research into DPP4 inhibitors for cardiovascular indications is warranted.